Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. [electronic resource]
Producer: 20120109Description: 713-5 p. digitalISSN:- 1742-1241
- Adult
- Biomarkers -- metabolism
- Cannabinoid Receptor Modulators -- antagonists & inhibitors
- Cholesterol -- metabolism
- Fatty Liver -- drug therapy
- Female
- Humans
- Hypercholesterolemia -- drug therapy
- Insulin Resistance -- physiology
- Male
- Middle Aged
- Non-alcoholic Fatty Liver Disease
- Obesity, Morbid -- drug therapy
- Piperidines -- therapeutic use
- Pyrazoles -- therapeutic use
- Retrospective Studies
- Rimonabant
- Safety-Based Drug Withdrawals
- Triglycerides -- metabolism
- Weight Loss -- drug effects
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.